Steini said: “The problem with all CAR-Ts so far is, apart from too expensive and complicated, they don't, because they can't, activate the patient's immune system. Cancer develops in every animal but the immune system is designed to take care of it. Cancer sufferers have the problem that their immune system isn't recognising the cancer and / or abe to produce the relevant T-cells and / or getting blocked.”
strongly disagree with this statement. CART has been proven to be extremely effective in treating blood cancers which has resulted in a paradigm shift in treatment for these patients. A lot of the research has focused on CD19 and more recently BCMA targets in these blood cancers. Multiple FDA approvals in this space.
whereas CART therapy for solid tumours has been less successful. However there are new CARTs which are targeting novel antigens such as CLDN18.2 such as CARGENs CART for gastric cancer which are showing excellent results. This is on track to be one of the first CART for solid tumours (if not the first) approved by the FDA. Currently in phase 1 in the US (phase 2+ in China). I note CARSGEN has a valuation over $1bn AUD on gong king exchange (recognise they have a couple other assets)
There are also newer generation CART designed to negotiate the solid tumour micro environment being trialled.
CHMs CART is a 3rd generation CART that is targeting a very novel antigen (CDH17) with compelling pre clinical data. That we have licensed from UPENN (pioneers of CART) for peanuts (single digit royalties and no milestone payments). Best deal Paul Hopper has ever inked according to the man himself!
CHM Price at posting:
0.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
